NMTC— NEUROONE MEDICAL TECHNOLOGIES Corp

Health Care$14M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Product revenue	$9.1M+163.5%	$3.5M+76.9%	$2.0M+1040.7%	$171K
Cost of product revenue	$4.0M+66.7%	$2.4M+58.7%	$1.5M+518.2%	$242K
Product gross profit	$5.1M+376.2%	$1.1M+136.5%	$457K+744.9%	-$71K
Collaborations revenue	$3.0M	—	—	$1.9M
Selling, general and administrative	$7.4M-6.5%	$7.9M+14.1%	$6.9M-0.8%	$7.0M
Research and development	$5.0M-1.6%	$5.1M-27.0%	$6.9M+40.8%	$4.9M
Total operating expenses	$12.4M-4.6%	$13.0M-6.5%	$13.9M+16.4%	$11.9M
Loss from operations	-$4.2M+64.4%	-$11.9M+0.6%	-$12.0M-19.2%	-$10.0M
Fair value change in warrant liability	$785K+339.9%	-$327K	—	—
Financing costs	-$334K-45.9%	-$229K	—	—
Other income, net	$170K+36.2%	$125K+30.7%	$96K+207.4%	$31K
Loss before income taxes	-$3.6M+70.7%	-$12.3M-3.9%	-$11.9M-18.6%	-$10.0M
Provision for income taxes	—	—	—	—
Net loss	-$3.6M+70.7%	-$12.3M-3.9%	-$11.9M-18.6%	-$10.0M
Basic (in Dollars per share)	-$0.09+80.4%	-$0.46+29.2%	-$0.65-3.2%	-$0.63
Diluted (in Dollars per share)	-$0.09+80.4%	-$0.46+29.2%	-$0.65	—
Basic (in Shares)	40.2M+50.0%	26.8M+47.7%	18.1M+13.3%	16.0M
Diluted (in Shares)	40.2M+50.0%	26.8M+47.7%	18.1M	—

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.